BGPT: Paper Review: Amicoumacin A Inhibits Translation by Stabilizing mRNA Interaction with the Ribosome

Explore by Goal

Quick Explanation Copied

Mechanism call:

Amicoumacin A (AMI) is presented as a 30S/16S rRNA–mRNA tethering inhibitor: AMI binds near helix 24 (h24) in the E-site platform, simultaneously contacting 16S rRNA (e.g., U788, A794, C795) and the mRNA backbone, and thereby impairs translocation (supported by resistance genetics + toe-printing/translocation assays + 2.4 Å co-crystal structure).

Long Explanation

Paper Review

Amicoumacin A Inhibits Translation by Stabilizing mRNA Interaction with the Ribosome

Target: translation machinery • Focus: 30S (16S rRNA) + mRNA tethering • Evidence tier: genetics + biochemistry + crystal structure

Primary source: 10.1016/j.molcel.2014.09.020

Visual map: proposed inhibitory mechanism

Binding site: AMI sits on the 30S platform near h24 in the E-site region, contacting 16S rRNA residues U788, A794, C795 and the mRNA backbone.
Core idea: By interacting with both 16S rRNA and mRNA backbone, AMI tethers/fixes the mRNA path relative to the small subunit, increasing energetic/kinetic barriers to translocation.
Functional tests: In vivo translation inhibition without strong RNA/DNA inhibition, reporter activation consistent with slower ribosome progression, and toe-printing/translocation assays showing AMI blocks EF-G–driven relocation.
Genetic modifiers: Resistance frequently maps to 16S rRNA h24 (A794G, C795U, etc.), and partially to EF-G domain IV mutations (e.g., G542V) that can compensate translation in AMI presence.

Key extracted quantitative data (from the paper text provided)

MIC (in vivo) for rrn mutant replacement strains

SQ110DTC (rrnB operon wild-type at A794 position): 0.5 mg/mL AMI.
SQ110DTC (rrsE A794G): >64 mg/mL.
SQ110DTC (rrsE C795U): 64 mg/mL.

In vitro translation inhibition (IC50)

IC50 in E. coli cell lysate translation extract (S30/cell extract): 0.45 ± 0.05 mM.
IC50 in PURE system (purified components): 0.20 ± 0.19 mM.

Plotly visualizations (data directly extracted from the provided text)

Note: only values explicitly present in the provided excerpt are graphed.

Data integrity note (skeptical check)

The MIC graph uses A794G as “≥64 mg/mL” but plots 64 as a lower-bound marker due to the excerpt showing >64. That prevents over-interpreting the magnitude beyond what is explicitly stated. 64" mg/mL; the authors also report C795U as 64 mg/mL and WT as 0.5 mg/mL." url="https://dx.doi.org/10.1016/j.molcel.2014.09.020" number-citations="1" descriptive-anchor-text="MIC table includes a lower-bound for A794G" evidence-strength="strong">

Mechanistic evidence—what is known vs inferred

(A) Known from experiments (high confidence)

AMI inhibits protein synthesis at concentrations comparable to its MIC, whereas RNA/DNA synthesis inhibition is absent at >100-fold higher concentrations in the macromolecular synthesis experiment described.
Resistance mapping implicates 16S rRNA: in the described rrn-reduced SQ110DTC selection, most resistant clones carry a single 16S rRNA change at/near A794 (A794G or C795U are explicitly named), with large MIC increases.
High-resolution structure locates AMI at the 30S platform between E-site mRNA backbone and 16S rRNA helix 24 loop, with explicit residue contacts and mRNA “affixing” interaction.
Functional inhibition of translocation is directly supported by an EF-G–initiated toe-printing translocation assay where AMI blocks relocation from Met codon position to the next codon position in a concentration-dependent manner.

(B) Inference (plausible, but not uniquely proven)

“Tethering → translocation block” causality is mechanistically plausible: AMI simultaneously binds 16S rRNA and mRNA backbone in the E site. However, the excerpt does not provide direct measurements of mRNA-relative motion in real time; the claim is therefore an inference based on structural geometry plus translocation readouts.
Why EF-G mutations compensate: the paper notes EF-G domain IV mutations can partially alleviate AMI inhibition but suggests multiple possible biochemical explanations (e.g., affecting ribosome protection-like equilibrium or altering functional properties). The precise molecular reconciliation is therefore not uniquely resolved in the provided text.

The paper compares AMI to pactamycin (PCT), arguing that while both overlap in binding site region on 30S, AMI “fastens” mRNA while PCT disrupts mRNA path by displacement; toe-printing behaviors in the described experiments are consistent with distinct mechanism.

Skeptical critique: limitations, blind spots, and what would disprove the claim

Potential limitations (from what’s stated in the paper excerpt)

Species/model transfer: the structure uses Thermus thermophilus ribosomes while the functional resistance/translation assays are in E. coli strains; generalization across bacteria is plausible given conserved nucleotides but still a source of uncertainty.
Conformational state ambiguity: the structural complexes use mRNA/tRNA species that “cannot form base-pairing interactions in the E site,” which the authors connect to an in vivo state prior to translocation after productive initiation; nonetheless, this can bias which AMI binding pose is captured.
Resistance spectrum: resistance determinants were mapped in laboratory selections; while major classes are identified (16S rRNA h24; EF-G; ksgA inactivation), the provided excerpt does not show whether clinical isolates would harbor different mechanisms.

What would disprove or weaken the main mechanism?

Even if AMI inhibits translation, the specific “mRNA tethering impedes translocation” story is only as good as its causal chain. The paper’s own logic implies these falsifiers (stated here as rigorous scientific checkpoints consistent with their discussion):

If AMI binding to the proposed h24 region did not correlate with translocation inhibition (e.g., if h24 mutations did not reduce AMI efficacy or if translocation inhibition persisted without h24 engagement), the mechanism would be weakened.
If EF-G compensation occurred without any change in translocation readouts, it would imply a different downstream consequence (not captured by the presented assays).

Author-review deep dives (jump links)

Click to open BGPT Author Review pages for named authors of this paper.

Feedback:

Updated: March 28, 2026